Tarek Alhamad, MD, MS, FACP, FASN

Tarek Alhamad, MD, MS, FACP, FASN

Professor of Medicine, Medical Director of Transplant Nephrology, Division of Nephrology

Additional Titles

  • Medical Director, Pancreas Transplant Program
  • Medical Director, Kidney Transplant Program

Location

Patients seen at

Map of location

Center for Advanced Medicine

Mailing Address

Division of Nephrology

  • Mailing Address: 660 S. Euclid Ave., CB 8126
    St. Louis, MO 63110

Education

  • Fellowship, Transplant Nephrology: Mayo Clinic, Scottsdale, AZ (2013-2014)
  • MS, Public Health Science: Penn State University, Hershey, PA (2010-2013)
  • Fellowship, General Nephrology: Penn State College of Medicine, Penn State University, Hershey, PA (2011-2013)
  • Residency, Internal Medicine: Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX (2008-2011)
  • MD: University of Damascus, Damascus, Syria (1999-2005)

Board Certifications

  • Nephrology, 2013-2023
  • Internal Medicine, 2011-2021

Recognition

2017
Poster of Distinction, American Transplant Congress, Chicago, IL

2016
Poster of Distinction, American Transplant Congress, Boston, MA.

2015
Poster of Distinction, American Transplant Congress, Philadelphia, PA

2013
Certificate of Excellence, Midwest Young Investigation Forum (YIF), Chicago, IL

2011
Research Recognition: Certificate of Excellence
Texas Tech University Health Sciences Center at El Paso, TX
Top Highlighted Posters, US Renal and Urology News
National Kidney Foundation (NKF) Annual Meeting, Las Vegas, NV

2009
Certificate of Merit – American College of Physicians

Clinical Interests

Antibody mediated rejection

Simultaneous pancreas and kidney transplantation

High-risk kidney transplantation

Recurrent glomerulonephritis

Research Interests

Acute and chronic rejection

Outcomes research in kidney and pancreas transplant

Recurrent glomerulonephritis

Clinical trials: Dr. Alhamad is the principal investigator of several pharmaceutical clinical trials examining the use of new medications and new diagnostic measures for better surveillance of kidney transplant.

Dr. Alhamad is also the site principal investigator of the Clinical Trials in Organ Transplantation (CTOT) from the National Institute of Health (NIH).